Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Elevance Health's Sloan Ratio for the quarter that ended in Jun. 2026 was -0.18%.
As of Jun. 2026, Elevance Health has a Sloan Ratio of -0.18%, indicating the company is in the safe zone and there is no funny business with accruals.
Elevance Health (MEX:ELV) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2026, Elevance Health has a Sloan Ratio of -0.18%, indicating the company is in the safe zone and there is no funny business with accruals.
Elevance Health Sloan Ratio % Related Terms
Elevance Health Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Elevance Health's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Healthcare Plans subindustry, Elevance Health's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elevance Health Sloan Ratio % vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, Elevance Health's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Elevance Health's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Elevance Health's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Elevance Health's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was 21811.254 (Sep. 2025 ) + 9849.118 (Dec. 2025 ) + 31809.683 (Mar. 2026 ) + 25527.887 (Jun. 2026 ) = MXN88,998 Mil.
Elevance Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was 20820.667 (Sep. 2025 ) + 1512.479 (Dec. 2025 ) + 78117.656 (Mar. 2026 ) + 33379.937 (Jun. 2026 ) = MXN133,831 Mil.
Elevance Health's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 was -22453.301 (Sep. 2025 ) + 8354.645 (Dec. 2025 ) + -29609.693 (Mar. 2026 ) + 2774.391 (Jun. 2026 ) = MXN-40,934 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elevance Health (MEX:ELV) has a Sloan Ratio % of -0.18% as of Jun. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Elevance Health and its competitors.
Is Elevance Health's Sloan Ratio % too high?
Elevance Health's current Sloan Ratio % is -0.18%. Overall, Elevance Health has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elevance Health's Sloan Ratio % compare to CI and HUM?
Elevance Health's Sloan Ratio % of -0.18% can be compared against companies in the Healthcare Plans industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Healthcare Plans company?
A good Sloan Ratio % depends on the Healthcare Plans industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Elevance Health and its competitors. Elevance Health's current Sloan Ratio % is -0.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elevance Health stock overvalued right now?
Based on GuruFocus' analysis, Elevance Health (MEX:ELV) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN7,798.18, compared to a current price of MXN6,449.00 — trading 17.3% below its estimated fair value. The current Sloan Ratio % is -0.18%. Elevance Health's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Elevance Health (MEX:ELV), the current Sloan Ratio % is -0.18% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elevance Health (MEX:ELV) Overvalued in 2026?
Based on GuruFocus' analysis, Elevance Health stock appears to be undervalued.
The current stock price of MXN6,449.00 is trading 17.3% below its estimated GF Value™ of MXN7,798.18.
GuruFocus considers Elevance Health to be Modestly Undervalued.
Key valuation signals for MEX:ELV:
Sloan Ratio %: -0.18%
GF Value™: MXN7,798.18 vs. price of MXN6,449.00 (17.3% below fair value)
No single metric tells the full story. See the MEX:ELV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
75GF Score
Get the complete analysis for MEX:ELV
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ELV has been successfully added to your 
